##  [COFEPRIS Announces New Simplification and Digitalization Measures for Pharmaceuticals](/index%2ephp/cofepris-announces-new-simplification-and-digitalization-measures-for-pharmaceuticals) 

2 min read 

[Spanish](/cofepris-anuncia-nuevas-medidas-de-simplificacion-y-digitalizacion-para-medicamentos)

  Your browser does not support the audio element.





The Federal Commission for the Protection against Sanitary Risks **(COFEPRIS) has announced new regulatory simplification measures** that will transform how pharmaceutical marketing authorizations are processed and maintained in Mexico. These actions aim to strengthen institutional efficiency through **digital process modernization**, the consolidation of a **one-stop regulatory window**, and the reduction of technical review timelines.

 The goal is clear: to build a more agile, transparent, and predictable COFEPRIS — one capable of responding to the dynamics of the pharmaceutical industry while ensuring continuous access to essential medicines in the country.

These actions form part of a broader **COFEPRIS regulatory simplification strategy**, focused on digital modernization and strengthening institutional trust.

## Key Simplification Measures

- **Digitalization of Procedures**   
    Implementation of the **DIGIPRiS** platform, which integrates online submission, tracking, and resolution of regulatory applications. This shift represents a deep step toward administrative modernization and the transition to a fully digital, paper-free COFEPRIS.
- **Reduced Review Timelines**   
    Shorter evaluation periods for drug applications and technical assessments, particularly for essential medicines.
- **Streamlined Administrative Requirements**  
    Updated forms, removal of redundant documents, and expanded use of electronic signatures.
- **Traceability and Transparency**  
    Real-time tracking of dossier status and direct communication channels with evaluators.

## Impact for the Pharmaceutical Industry

For companies with active or upcoming submissions, these measures require an operational reconfiguration.

  
Digitalization demands greater documentation consistency, stronger technical response capability, and a more robust internal alignment across Regulatory Affairs, Quality, and Pharmacovigilance functions.

The benefits are clear:

- reduced administrative burden,
- more predictable timelines,
- and incremental alignment with international*regulatory reliance*

However, the transition requires investment in training, digital infrastructure, and operational risk management.

In an environment where verified digital information becomes a **strategic asset**, organizations that anticipate and adapt their internal systems will be the best positioned to leverage the efficiencies of this new COFEPRIS framework.

## Strategic Tips and Recommended Actions

- Audit internal processes and verify the compatibility of current systems with COFEPRIS’ digital platforms.
- Update user profiles and access permissions in DIGIPRiS to ensure full traceability, control, and security.
- Implement electronic-signature controls and document-validation workflows.
- Strengthen coordination between regulatory and quality teams to meet the new response timelines.
- Consider expert support to optimize regulatory operations and post-approval maintenance.

## Final Insight

Regulatory simplification does not imply less rigor — it reflects a shift toward institutional maturity, efficiency, and digital evolution. Mexico is taking a decisive step toward regulatory modernization, and companies that adapt quickly will gain **greater agility, predictability, and competitiveness** in their operations.

With a solid regulatory strategy and support from experts in regulatory intelligence and COFEPRIS digitalization, organizations can move from basic compliance to **operational excellence**.

At Freyr, we help pharmaceutical companies plan and execute regulatory strategies that ensure compliance, efficiency, and sustained market access.

  
**Need to optimize your regulatory strategy in Mexico or LATAM?**[**Contact us**](https://bit.ly/FreyrLATAM_Contact)